ASSIST offices will be closed on Monday, September 2 for the Labor Day holiday

Healthcare Providers Patients & Caregivers

Paying For Orenitram

Orenitram Co-Pay Assistance Card

For patients with commercial or private insurance plans, we offer a co-pay card to help patients cover some of their out-of-pocket expenses.

contact assist

Most eligible patients pay as little as a $0.00 co-pay per month for Orenitram. The Orenitram Co-Pay Assistance program will automatically pay the difference up to a monthly maximum program benefit.*

Terms and Conditions

*Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.

Patient Assistance Program (PAP)

United Therapeutics offers a free medication program for uninsured and underinsured patients who meet eligibility requirements.

Call ASSIST at 1-877-864-8437 to find out if your patient qualifies for financial support.

Patients with commercial and/or employer funded insurance plans requiring them to apply to United Therapeutics ASSIST Patient Assistance Program as a prerequisite to or requirement for coverage of United Therapeutics Corporation products, commonly known as alternate funding programs (also referred to as specialty carve-outs, patient advocacy programs, or specialty networks) are not eligible for United Therapeutics ASSIST Patient Assistance Program.

Questions?

You can call ASSIST at 1-877-864-8437, Monday - Friday, 8:30am to 7:00pm ET or email ASSIST at assist@unither.com.

Important Reminder

Please remind your patients to keep the Specialty Pharmacy informed about their current insurance status.

Indication

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.

The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

IMPORTANT SAFETY INFORMATION FOR ORENITRAM

CONTRAINDICATIONS

Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

WARNINGS AND PRECAUTIONS

Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.

OThe Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

ADVERSE REACTIONS

In the 12-week, placebo-controlled, monotherapy study, and an event-driven, placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

DRUG INTERACTIONS

Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

SPECIFIC POPULATIONS

Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.

It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

Safety and effectiveness of Orenitram in pediatric patients have not been established.

Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.

There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

OREISIhcpOCT19

For additional information please see Full Prescribing Information or call Customer Service at 1-877-UNITHER (1-877-864-8437)

All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.

© 2024 United Therapeutics Corporation. All rights reserved.

07/21 US-ASSIST-0177